Equities analysts expect that Acer Therapeutics Inc (NASDAQ:ACER) will announce earnings per share of ($0.62) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Acer Therapeutics’ earnings. Acer Therapeutics posted earnings per share of ($1.04) in the same quarter last year, which suggests a positive year-over-year growth rate of 40.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, March 27th.
On average, analysts expect that Acer Therapeutics will report full year earnings of ($1.48) per share for the current year. For the next year, analysts anticipate that the business will post earnings of ($2.76) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Acer Therapeutics.
Acer Therapeutics (NASDAQ:ACER) last released its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter.
Shares of Acer Therapeutics (NASDAQ ACER) opened at $17.04 on Friday. Acer Therapeutics has a 1 year low of $5.70 and a 1 year high of $22.63. The firm has a market cap of $128.10, a P/E ratio of -4.23 and a beta of 2.58.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2018/02/10/zacks-analysts-expect-acer-therapeutics-inc-acer-will-post-earnings-of-0-62-per-share.html.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.